Meeting
2023 ASCO Annual Meeting
Pilot study of a micro-organosphere drug screen platform to lead care in advanced breast cancer (MODEL-ABC).
Authors
David Graham
Xilis, Durham, NC
David Graham , Gabrielle Rupprecht , Wylie Watlington , Jaycee Cushman , Angelica Montalvo , Samantha Womack , Caroline Morales , Samantha M. Thomas , Steven Metzger , Xiling Shen , Jeremy Meyer Force
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Clinical Trial Registration Number
NCT04655573
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1107)
DOI
10.1200/JCO.2023.41.16_suppl.1107
Abstract #
1107
Poster Bd #
328
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.
First Author: Eric P. Winer
Poster
2019 ASCO Annual Meeting
Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial.
First Author: Johannes Ettl
Poster
2018 ASCO Annual Meeting
EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation.
First Author: Hope S. Rugo
Poster
2023 ASCO Annual Meeting
Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.
First Author: Nagi S. El Saghir